The disclosure relates to medical devices and in particular to devices and methods that generates and delivers therapeutic electrical treatment pulses used in medical devices, such as cardioverters and defibrillators, neuro-stimulators, musculo-skeletal stimulators, organ stimulators and nerve/peripheral nerve stimulators. More specifically the disclosure relates to the generation and delivery/use by such medical devices of a new and innovatively shaped family/generation of biphasic or multiphasic pulse waveforms.
It is well known that a signal having a waveform may have a therapeutic benefit when the signal is applied to a patient. For example, the therapeutic benefit to a patient may be a treatment that is provided to the patient. The therapeutic benefit or therapeutic treatment may include stimulation of a part of the body of the patient or treatment of a sudden cardiac arrest of the patient. Existing systems that apply a signal with a waveform to the patient often generate and apply a well-known signal waveform and do not provide much, or any, adjustability or variability of the signal waveform.
In the context of defibrillators or cardioverters, today's manual defibrillators deliver either an older style Monophasic Pulse (a single high energy single polarity pulse) or the now more common Biphasic Pulse (consisting of an initial positive high energy pulse followed by a smaller inverted negative pulse). Today's implantable cardioverter defibrillators (ICDs), automated external defibrillators (AEDs) and wearable cardioverter defibrillators (WCDs) all deliver Biphasic Pulses with various pulse phase lengths, high initial starting pulse amplitude and various pulse slopes. Each manufacturer of a particular defibrillator, for commercial reasons, has their own unique and slightly different exact timing and shape of the biphasic pulse for their devices' pulses, although they are all based off of the standard biphasic waveform design. Multiple clinical studies over the last couple of decades have indicated that use of these variants of the biphasic waveform has greater therapeutic value than the older monophasic waveform does to a patient requiring defibrillation therapy and that these standard biphasic waveforms are efficacious at appreciably lower levels of energy delivery than the original monophasic waveforms, and with a higher rate of resuscitation success on first shock delivery.
Thus, almost all of the current defibrillator products that use a biphasic waveform pulse have a single high-energy reservoir, which, while simple and convenient, results in severe limitation on the range of viable pulse shapes that can be delivered. Specifically, the second (or Negative) phase of the Biphasic waveform is currently characterized by a lower amplitude starting point than the first (or Positive) phase of the Biphasic waveform, as shown in
The standard biphasic pulse waveform has been in common usage in manual defibrillators and in AEDs since the mid-1990s, and still results in energy levels of anywhere from 120 to 200 joules or more being delivered to the patient in order to be efficacious. This results in a very high level of electrical current passing through the patient for a short period of time which can lead to skin and flesh damage in the form of burns at the site of the electrode pads or paddles in addition to the possibility of damage to organs deeper within the patient's body, including the heart itself. The significant amounts of energy used for each shock and the large number of shocks that these AED devices are designed to be able to deliver over their lifespan, has also limited the ability to further shrink the size of the devices.
WCDs generally need to deliver shocks of 150-200 joules in order to be efficacious, and this creates a lower limit on the size of the electrical components and the batteries required, and hence impacts the overall size of the device and the comfort levels for the patient wearing it.
ICDs, given that they are implanted within the body of patients, have to be able to last for as many years as possible before their batteries are exhausted and they have to be surgically replaced with a new unit. Typically ICDs deliver biphasic shocks of up to a maximum of 30-45 joules, lower than is needed for effective external defibrillation as the devices are in direct contact with the heart tissue of the patient. Subcutaneous ICDs, differ slightly in that they are not in direct contact with the heart of the patient, and these generally deliver biphasic shocks of 65-80 joules in order to be efficacious. Even at these lower energy levels there is significant pain caused to the patient if a shock is delivered in error by the device. Most existing devices are designed to last for between 5-10 years before their batteries are depleted and they need to be replaced.
Another, equally common type of defibrillator is the Automated External Defibrillator (AED). Rather than being implanted, the AED is an external device used by a third party to resuscitate a person who has suffered from sudden cardiac arrest.
A typical protocol for using the AED 800 is as follows. Initially, the person who has suffered from sudden cardiac arrest is placed on the floor. Clothing is removed to reveal the person's chest 808. The pads 804 are applied to appropriate locations on the chest 808, as illustrated in
The novel biphasic or multiphasic pulse waveform is applicable for use with various medical devices including all defibrillator types: external (manual, semi-automated and fully automated), wearable and implanted. In addition to defibrillators, the medical device may also be cardioverters and external/internal pacers, as well as other types of electrical stimulation medical devices, such as: neuro-stimulators, musculo-skeletal stimulators, organ stimulators and nerve/peripheral nerve stimulators, whether the devices are external or implantable. The biphasic or multiphasic waveform pulse may be particularly useful for any type of defibrillator and examples of the biphasic or multiphasic waveform pulse will be described in the context of a defibrillator for illustration purposes.
The novel biphasic or multiphasic waveform pulse is a distinctly different family of waveforms compared to the standard biphasic waveforms (see
The novel biphasic or multiphasic waveform pulse allows for an efficacious pulse waveform to be delivered to the patient at a substantially lower level of total energy than ever before. In preclinical animal trials using the novel biphasic or multiphasic waveform pulse, successful defibrillation has been demonstrated using the novel biphasic or multiphasic waveform pulse, repeatedly, and at significantly lower levels of total delivered energy than the energy required by any current external defibrillators using either the original monophasic pulse or the now traditional biphasic pulse. For example, the novel biphasic or multiphasic waveform pulse may deliver 0.1 to 200 joules to a patient. Furthermore, the time for the waveform pulse delivery is between 1-20 ms and preferably 8-10 ms for the combined first and second phases of the waveform, although for triphasic and quadriphasic waveforms this is preferably in the 8-16 ms range for the entire waveform. For an embodiment in which the generated waveform is being used for nerve stimulation or neuro-stimulation, the waveform period may be on the order of microseconds or shorter.
The novel biphasic or multiphasic waveform pulse also significantly reduces both the total energy and the current levels that must be discharged into the patient, thus reducing the chance of either skin burns or other damage to the skin, tissue or organs of the patient. The novel biphasic or multiphasic waveform pulse also reduces the maximum amount of energy that a device is required to store and deliver, and it increases the maximum lifespan of any battery powered device due to a more frugal use of the energy stored within it. The novel biphasic or multiphasic waveform pulse also enables the production of smaller devices as a lower total amount of energy is needed to be stored and delivered to the patient.
The novel biphasic or multiphasic waveform pulse is effective across a wide range of values for multiple variables/characteristics of the novel biphasic or multiphasic waveform pulse. For example,
In an additional embodiment, the novel biphasic or multiphasic waveform pulse may have different phase tilts for either or both phases as shown in
The novel biphasic or multiphasic waveform pulse may be generated in various manners. For example, as shown in
While the foregoing has been with reference to a particular embodiment of the disclosure, it will be appreciated by those skilled in the art that changes in this embodiment may be made without departing from the principles and spirit of the disclosure, the scope of which is defined by the appended claims.
This application is a continuation in part of and claims priority under 35 USC 120 to U.S. patent application Ser. No. 14/303,541, filed on Jun. 12, 2014 and entitled “Dynamically Adjustable Multiphasic Defibrillator Pulse System And Method” which in turn claims priority under 35 USC 120 and claims the benefit under 35 USC 119(e) to U.S. Provisional Patent Application Ser. No. 61/835,443 filed Jun. 14, 2013 and titled “Dynamically Adjustable Multiphasic Defibrillator Pulse System and Method”, the entirety of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4441498 | Nordling | Apr 1984 | A |
5199429 | Kroll et al. | Apr 1993 | A |
5240995 | Gyory et al. | Aug 1993 | A |
5290585 | Elton | Mar 1994 | A |
5338490 | Dietz et al. | Aug 1994 | A |
5362420 | Itoh et al. | Nov 1994 | A |
5402884 | Gilman et al. | Apr 1995 | A |
5489624 | Kantner et al. | Feb 1996 | A |
5536768 | Kantner et al. | Jul 1996 | A |
5573668 | Grosh et al. | Nov 1996 | A |
5643252 | Waner et al. | Jul 1997 | A |
5658316 | Lamond et al. | Aug 1997 | A |
5660178 | Kantner et al. | Aug 1997 | A |
5733310 | Lopin et al. | Mar 1998 | A |
5800685 | Perrault | Sep 1998 | A |
5871505 | Adams | Feb 1999 | A |
5987354 | Cooper | Nov 1999 | A |
6004312 | Finneran et al. | Dec 1999 | A |
6006131 | Cooper | Dec 1999 | A |
6056738 | Marchitto et al. | May 2000 | A |
6141584 | Rockwell et al. | Oct 2000 | A |
6197324 | Crittenden | Mar 2001 | B1 |
6251100 | Flock et al. | Jun 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6266563 | Kenknight et al. | Jul 2001 | B1 |
6315722 | Yaegashi | Nov 2001 | B1 |
6329488 | Terry et al. | Dec 2001 | B1 |
6379324 | Gartstein et al. | Apr 2002 | B1 |
6477413 | Sullivan et al. | Nov 2002 | B1 |
6576712 | Feldstein et al. | Jun 2003 | B2 |
6596401 | Terry et al. | Jul 2003 | B1 |
6597948 | Rockwell et al. | Jul 2003 | B1 |
6611707 | Prausnitz et al. | Aug 2003 | B1 |
6690959 | Thompson | Feb 2004 | B2 |
6714817 | Daynes et al. | Mar 2004 | B2 |
6797276 | Glenn et al. | Sep 2004 | B1 |
6803420 | Cleary et al. | Oct 2004 | B2 |
6908453 | Fleming et al. | Jun 2005 | B2 |
6908681 | Terry et al. | Jun 2005 | B2 |
6931277 | Yuzhakov et al. | Aug 2005 | B1 |
7072712 | Kroll et al. | Jul 2006 | B2 |
7108681 | Gartstein et al. | Sep 2006 | B2 |
7215991 | Besson et al. | May 2007 | B2 |
7226439 | Prausnitz et al. | Jun 2007 | B2 |
7463917 | Martinez | Dec 2008 | B2 |
7645263 | Angel et al. | Jan 2010 | B2 |
7797044 | Covey et al. | Sep 2010 | B2 |
8024037 | Kumar | Sep 2011 | B2 |
8527044 | Edwards et al. | Sep 2013 | B2 |
8558499 | Ozaki et al. | Oct 2013 | B2 |
8615295 | Savage et al. | Dec 2013 | B2 |
8781576 | Savage et al. | Jul 2014 | B2 |
9089718 | Owen et al. | Jul 2015 | B2 |
9101778 | Savage et al. | Aug 2015 | B2 |
9616243 | Draymond et al. | Apr 2017 | B2 |
9656094 | Raymond et al. | May 2017 | B2 |
20010031992 | Fishler et al. | Oct 2001 | A1 |
20020016562 | Cormier et al. | Feb 2002 | A1 |
20020045907 | Sherman et al. | Apr 2002 | A1 |
20020082644 | Picardo et al. | Jun 2002 | A1 |
20030017743 | Picardo et al. | Jan 2003 | A1 |
20030055460 | Owen et al. | Mar 2003 | A1 |
20030088279 | Rissmann et al. | May 2003 | A1 |
20030125771 | Garrett et al. | Jul 2003 | A1 |
20030167075 | Fincke | Sep 2003 | A1 |
20030197487 | Tamura et al. | Oct 2003 | A1 |
20040105834 | Singh et al. | Jun 2004 | A1 |
20040143297 | Maynard, III | Jul 2004 | A1 |
20040166147 | Lundy et al. | Aug 2004 | A1 |
20040247655 | Asmus et al. | Dec 2004 | A1 |
20050055460 | Johnson et al. | Mar 2005 | A1 |
20050107713 | Van Herk | May 2005 | A1 |
20050123565 | Subramony et al. | Jun 2005 | A1 |
20060136000 | Bowers | Jun 2006 | A1 |
20060142806 | Katzman et al. | Jun 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060206152 | Covey et al. | Sep 2006 | A1 |
20070016268 | Carter et al. | Jan 2007 | A1 |
20070078376 | Smith | Apr 2007 | A1 |
20070135729 | Ollmar et al. | Jun 2007 | A1 |
20070143297 | Recio et al. | Jun 2007 | A1 |
20070150008 | Jones et al. | Jun 2007 | A1 |
20070191901 | Schecter | Aug 2007 | A1 |
20080082153 | Gadsby et al. | Apr 2008 | A1 |
20080097546 | Powers et al. | Apr 2008 | A1 |
20080154110 | Burnes et al. | Jun 2008 | A1 |
20080154178 | Carter et al. | Jun 2008 | A1 |
20080177342 | Snyder | Jul 2008 | A1 |
20080312579 | Chang et al. | Dec 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090005827 | Weintraub et al. | Jan 2009 | A1 |
20090076366 | Palti | Mar 2009 | A1 |
20090210022 | Powers | Aug 2009 | A1 |
20090318988 | Powers | Dec 2009 | A1 |
20090326400 | Huldt | Dec 2009 | A1 |
20100063559 | McIntyre et al. | Mar 2010 | A1 |
20100160712 | Burnett et al. | Jun 2010 | A1 |
20100181069 | Schneider et al. | Jul 2010 | A1 |
20100191141 | Aberg | Jul 2010 | A1 |
20100241181 | Savage et al. | Sep 2010 | A1 |
20100249860 | Shuros et al. | Sep 2010 | A1 |
20110028859 | Chian | Feb 2011 | A1 |
20110071611 | Khuon et al. | Mar 2011 | A1 |
20110208029 | Joucla et al. | Aug 2011 | A1 |
20110237922 | Parker, III et al. | Sep 2011 | A1 |
20110288604 | Kaib et al. | Nov 2011 | A1 |
20110301683 | Axelgaard | Dec 2011 | A1 |
20120101396 | Solosko et al. | Apr 2012 | A1 |
20120112903 | Kaib et al. | May 2012 | A1 |
20120136233 | Yamashita | May 2012 | A1 |
20120158075 | Kaib et al. | Jun 2012 | A1 |
20120158078 | Moulder et al. | Jun 2012 | A1 |
20120203297 | Efimov et al. | Aug 2012 | A1 |
20120259382 | Trier | Oct 2012 | A1 |
20130018251 | Caprio et al. | Jan 2013 | A1 |
20130144365 | Kipke et al. | Jun 2013 | A1 |
20140005736 | Geheb | Jan 2014 | A1 |
20140039593 | Savage et al. | Feb 2014 | A1 |
20140039594 | Savage et al. | Feb 2014 | A1 |
20140221766 | Kinast | Aug 2014 | A1 |
20140276183 | Badower | Sep 2014 | A1 |
20140277226 | Poore et al. | Sep 2014 | A1 |
20140317914 | Shaker | Oct 2014 | A1 |
20140371566 | Raymond et al. | Dec 2014 | A1 |
20140371567 | Raymond et al. | Dec 2014 | A1 |
20140371805 | Raymond et al. | Dec 2014 | A1 |
20140371806 | Raymond et al. | Dec 2014 | A1 |
20150297104 | Chen et al. | Oct 2015 | A1 |
20150327781 | Hernandez-Silveira et al. | Nov 2015 | A1 |
20160206893 | Raymond et al. | Jul 2016 | A1 |
20160213933 | Raymond et al. | Jul 2016 | A1 |
20160213938 | Raymond et al. | Jul 2016 | A1 |
20160296177 | Gray et al. | Oct 2016 | A1 |
20160361533 | Savage et al. | Dec 2016 | A1 |
20160361555 | Savage et al. | Dec 2016 | A1 |
20170252572 | Raymond et al. | Sep 2017 | A1 |
Number | Date | Country |
---|---|---|
10 2006 02586 | Dec 2007 | DE |
1 530 983 | May 2005 | EP |
1 834 622 | Sep 2007 | EP |
2000-093526 | Jan 1917 | JP |
2011-512227 | Sep 1917 | JP |
2012-501789 | Sep 1917 | JP |
S63-296771 | Sep 1917 | JP |
2007-530124 | Nov 2007 | JP |
2005-14416 | Jun 2008 | JP |
2008-302254 | Dec 2008 | JP |
2010-511438 | Apr 2010 | JP |
2010-529897 | Sep 2010 | JP |
2012-135457 | Jul 2012 | JP |
2012-529954 | Nov 2012 | JP |
WO 03020362 | Mar 2003 | WO |
WO 2010146492 | Dec 2010 | WO |
WO2010151875 | Dec 2010 | WO |
Entry |
---|
PCT International Preliminary Report on Patentability of PCT/US2010/027346 dated Sep. 20, 2011 (12 pages). |
PCT International Search Report of PCT/US10/27346; dated Oct. 14, 2010 (4 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US10/27346; dated Oct. 14, 2010 (7 pgs.). |
PCT International Preliminary Report on Patentability of PCT/US12/65712; dated Jun. 10, 2014 (6 pgs.). |
PCT International Search Report of PCT/US2012/065712, dated Mar. 29, 2013 (2 pages). |
PCT International Search Report of PCT/US14/42355; dated Nov. 3, 2010 (2 pgs.). |
PCT Written Opinion of PCT/US2012/065712, dated Mar. 29, 2013 (5 pages). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42355; dated Nov. 3, 2014 (6 pgs.). |
PCT International Search Report of PCT/US14/42356; dated Nov. 3, 2010 (2 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42356; dated Nov. 3, 2014 (6 pgs.). |
PCT International Search Report of PCT/US14/42360; dated Nov. 4, 2010 (2 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42360; dated Nov. 4, 2014 (4 pgs.). |
PCT International Search Report of PCT/US14/42409; dated Nov. 4, 2010 (2 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42409; dated Nov. 4, 2014 (4 pgs.). |
PCT International Preliminary Report on Patentability and Written Opinion of PCT/EP2007/009879; dated May 19, 2009 (7 pages). |
PCT International Search Report of PCT/EP2007/009879; dated Apr. 29, 2008 (3 pages). |
PCT International Written Opinion of PCT/EP2007/009879; dated Apr. 29, 2008 (6 pages). |
Chinese First Office Action of CN 201080021650.4 (English and Chinese); dated Jul. 24, 2013 (19 pgs.). |
Chinese Second Office Action of CN 201080021650.4 (English and Chinese); dated Jan. 16, 2014 (16 pgs.). |
Chinese Third Office Action of CN 201080021650.4 (English and Chinese); dated Jun. 17, 2014 (18 pgs.). |
Japanese Notification of Reason for Rejection of JP 2012-500855 (English and Japanese); dated Feb. 17, 2014 (3 pgs.). |
Extended European Search Report of EP 2408521 dated Jul. 10, 2012 (8 pages). |
“Changes in the passive electrical properties of human stratum corneum due electroporation” dated Dec. 7, 1994. By U. Pliquett, R. Langer, and J. C. Weaver (11 pages). |
“Electrical properties of the epidermal stratum corneum” dated Aug. 12, 1974. By T. Yamamoto and Y. Yamamoto (8 pages). |
“Non-invasive bioimpedance of intact skin: mathematical modeling and experiments” dated May 2, 2010. By U. Birgersson, E. Birgersson, P. Aberg, I. Nicander, and S. Ollmar (19 pages). |
Polymer Microneedles for Controlled-Release Drug Delivery dated Dec. 2, 2005. By J-H. Park, M. G. Allen, and M. R. Prausnitz (12 pages). |
“Utilizing Characteristic Electrical Properties of the Epidermal Skin Layers to Detect Fake Fingers in Biometric Fingerprint Systems—A Pilot Study” dated Dec. 1, 2004. By O. G. Martinsen, S. Clausen, J. B. Nysaether, and S. Grimnes (4 pages). |
“Lack of Pain Associated with Microfabricated Microneedles” dated Oct. 10, 2000. By S. Kaushik, A. H. Hord, D. D. Denson, D. V. McAlliser, S. Smitra, M. G. Allen, and M. R. Prausnitz (3 pages). |
“Two Dimensional Metallic Microelectrode Arrays for Extracellular Stimulation and Recording of Neurons” dated 1993. By A. B. Frazier, D. P. O'Brien, and M. G. Allen (6 pages). |
“Insertion of microneedles into skin: measurement and prediction of insertion force and needle facture force” dated Dec. 10, 2003. By S. P. Davis, B. J. Landis, Z. H. Adams, M. G. Allen, and M. R. Prausnitz (9 pages). |
“Microneedle Insertion Force Reduction Using Vibratory Actuation” dated 2004. By M. Yang and J. D. Zahn (6 pages). |
Yoshio Yamanouchi, et al., Optimal Small-Capacitor Biphasic Waveform for External Defibrillation; Influence of Phase-1 Tilt and Phase-2 Voltage, Journal of the American Heart Association, Dec. 1, 1998, vol. 98, pp. 2487-2493 (8 pgs.). |
Number | Date | Country | |
---|---|---|---|
20160213938 A1 | Jul 2016 | US |
Number | Date | Country | |
---|---|---|---|
61835443 | Jun 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14303541 | Jun 2014 | US |
Child | 14662137 | US |